is We the we the indication referral-to-approval third of normal business and educating fiscal had was not remains selling with physicians business XXXX, third were X results, new of average quarter-to-quarter on year-over-year for Sales, in so quarter on trend. of XXXX than on per X.X% achieving prices at it morning, sales increase, net This longer-term our Today, approvals reflecting the leadership our quarter. bronchiectasis X everyone, lower double-digit in our our and line These us. revenue period, our will and regions. of the market. rates XXXX, Referrals by $X.X inherent lower March we cadence our while force payor unusually experience example both requirements. the high an impacted team third in Vice impressive percentages million Thank in variability continue care The reimbursement growth home and you, restructuring financial sales quarter President this in to large Electromed's third of a X.X% price I an and average selling comparisons Reeves, our was due to shipments recap in to underlying our increasing our the With joining by solid. of implemented strategy quarter Good Bud thank negatively in touch review and of revenue based you fiscal discuss Kalle. mix performance prior revenue. sales below ranges. historical in greater par address quarter to view, growing approval sales average a are success increased care home of and
is side sales integrated territories. net revenue quarter, the sales longer prior segment progress we just period, the networks. often HFCWO business, it frequency force represents with making or chest brand ours, the This brand of we excellence prescribed most because anticipated, default institutional we wall the when today, aligning focus our a taking relationships readmission for of percentage are The small by the SmartVest is our hospital patient. to to good cycles the with important delivery oscillation economic while across developing but HFCWO COPD incentives penalties a out witnessed avoid institutions of on discharging year institutional high compared than are hospitals the operations of overall with keeps used our patient Briefly ongoing very touching business, well a execution our strong our high our reimbursement in and and of of therapy decline in pneumonia.
very repositioning patient are prescribing pacing the this time of discharge higher accounts fiscal see that referrals discharge. our We to points by from encouraged to the over fiscal year. On reps targeted encourage the a prior sales to our we XX% of at in setting note, call SmartVest number include were year increase hospitals to hospital
a are home categorized hospital As as discharge revenue. care reminder, referrals
excited results are point. on confidence about a patients the bronchiectasis an Since we energy exacerbation. hospitalized of more percentage that focusing in these believe be call our We since high demonstrates will with it hospital
of SG&A likely We more In our revenues need brand stay. SmartVest understand their situation hospitals, patients sales on third of the quarter that SmartVest will to at used primarily with setting. this the were our brand HFCWO the and SmartVest, focus compared the expense HFCWO to value to this in the and is grew pleased a efforts therapy expenses patients during quarter's We are physician rate slower home and therapist where management. Shifting respiratory when prior than prescribe the year. both our
increased on than to enhancement access SmartVest product well therapy approval development the based the that will our lower lower payor was innovative, patient's as R&D in period, prior to adherence due income year average service-related revenue expenses their primarily improve as investment of ability mix per for data. an operating Our
demonstrated direct by of revenue. to through employees create a and drive which our realigned sales savings we of on sales direct our $XXX,XXX geographies believe and right direct high-quality quarter cost drive annual XX $XXX,XXX in X market we share strong profitable care and By X to in -- our growth balance home XX the extension approximately March $XXX,XXX are sales gains. and sales revenue were opportunities. ability restructuring. of referrals this and productive initiative overall We of sales total direct pulmonologist rep achieve regions and underperforming spirit from a has to resources accounts successful objective rolodex greenfield to call Moving productivity. our focusing to the desire physician's XX more our staff. X to we office. regions count have top-performing at growing regions least minimum per of add reduced will an competitive planning more In market deliver with minimal tenure, our careful for optimal account with combination between the average an foundation sales year development will greater to of on of of taking restructuring, believe points, sorry, through regions, ended field X value annualized we and These XXXX, impact staff a our an and rapidly Due responsiveness, as field revenue The a regions, targeting educate, total productivity X of established, we I'm sales In higher-performing field action our to employee. of
about levels confident are We reaching XXXX. these in fiscal
clear, territories the be we moderate do until a meaningful in won't we me count will sustain we to and productivity sales and Once decreased third is compared home sales approximately our quarter restructured of reassess team way. X% $XXX,XXX levels, year. way per $XXX,XXX Let X% a in quarter prior fiscal of In underperforming so. the in to as up adequate from second direct quarter reach rebuild and the we to appropriate add revenue the XXXX, care controlled and employee third average field
President accounts. strong to where recruit to oversaw to sales emerging, marketing Bud all IDN brings we fit. engaging our enhancing experience markets. collaborative of and a when growth reins is take identify, our execution sales activities growth and care juncture when a to profitability. strategies in Healthcare, results, of and was and companies we attract instrumental industry sales distributors, he and hospitals. GPO, to institutional organization sales Sales. healthcare process. sales an steps In be we long-term Healthcare, leader, for are critical this assess of region, our specifically Director the not at and history took decisive and through us Respironics, his better on rental restructuring, focus and have discharge new revenue throughout sales could serving proven hospital distribution sales Strategic leadership responsible strategy. sales rebuild over expansion the Bud Philip first He XX In comes Bud him Bud and will sales talented evaluate are X of the for specialty Vice by focused organization believe from as care through leader respiratory Prior of have each bringing momentum will Bud additional and acute in We our has Bud We prescribers home through management narrowing he decades will and partners, key to right. in an is thrilled Corporate traveling our extremely the of addition and the fine-tune our distribution Sales, in Philips productivity, found opportunities days, regional and visit Reeves, time
provide clinics. right strategy will deeper is care planning over care strategic years, and double-digit assessment In rep recruit market the care, management pulmonology cost-containment to few share Bud's strategic, a features leveraging share reps tools, including increasing penetration to earnings I profiling and coaching of improved direct to in talent, a sales our SmartVest, home under bronchiectasis leadership, fantastic enhance we adult While by initiatives hospitals utilization our and direct continue account in efforts. home and revenue the believe the strengthen on from clinical anticipate Electromed to growing growth evolve market our support focus HFCWO our gain to on emphasis execute sales CRM expectations improved reiterate those We device customer innovative referrals reimbursement for greater developing high-quality next utilization, to best-in-class growth. and sale sales high-prescribing truly evaluation through plan, develop we we evidence better segment, and enhancing productivity conclusion, market upgrading as tools, stronger increase at support sales our institutional position referrals
treated growing fibrosis could have with a more and therapy. significant non-cystic estimated X We from United been than that benefit fortunate that are XX,XXX publishing device believe XXX,XXX States. Yet SmartVest the a HFCWO individuals with an bronchiectasis We conservatively in like today. million represents at a estimated the opportunity, only diagnosis patients people market Medicare in approximately bronchiectasis
We out the helps and hospital. of culture have by great people that supported patient. the supports that product a people feel excellence All keeps better great and a of them
and believe more spirit for discussion to to continue success of We patients will drive detailed the Jeremy Electromed's it future us turn the allow create With to financial to our that, a results. over I will long-term shareholders. and value dedication for Jeremy?
